Chemotherapy in Women with Breast Cancer

  1. James Liebmann, MD;
  2. Clark Haskins, MD;
  3. Barbara McAneny, MD;
  4. Richard Giudice, MD;
  5. Douglas Clark, MD; and
  6. Natalie Marshall, MD
  1. From New Mexico Cancer Center; Albuquerque, NM 87109.

    The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

    •Include no more than 300 words of text, three authors, and five references

    •Type with double-spacing

    •Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

    Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

    Annals welcomes electronically submitted letters.

    TO THE EDITOR:

    Du and colleagues (1) reported that in New Mexico between 1991 and 1997, only 29% of women with a diagnosis of early-stage breast cancer received adjuvant chemotherapy. …

    « Previous | Next Article »Table of Contents